secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-126382
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma Q3 2024: revenue $8.5M, cash $388.3M, luvelta registrational trial underway
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $388.3M as of September 30, 2024.
- Revenue $8.5M for Q3 2024, down from $16.9M in Q3 2023 (49.7% decrease).
- Total operating expenses $76.4M, up from $60.9M in Q3 2023; R&D $62.1M, G&A $14.3M.
- Realized gain of $32.1M from sale of Vaxcyte shares; no remaining Vaxcyte holdings.
- Initiated registrational trial for luvelta in pediatric leukemia; IND for STRO-004 expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/0000950170-24-126382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/stro-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer